ICN to organize virtual discussion on "Digital Transformation: The Catalyst for Agile and Smarter Process" on June 4

Speakers for the session are: Dr. Richard Lobo, Global Head Business Excellence, Innovation, R&D and Chief Ethics Counsellor, Tata Chemicals; Dr. Debabrata Rautaray, Vice President and Chief Product Development & Innovation Officer, DCM Shriram Chemicals Innovation Centre; Dr. Prashant Puri, Head - R&D, Deepak Fertilizers and Petrochemicals Corporation (DFPCL); Dr. Deepak S Panmand, General Manager (R&D), Dhanuka Agritech; Dr. Mudassir. K. Munshi, Team Leader, Deepak Nitrite; and Dr. Manish M. Khandagale, Senior Field Application Specialist, Revvity Signals

Asahi Kasei establishes Asahi Kasei Life Science to drive its bioprocess businesses

Asahi Kasei Life Science covers a broad range of bioprocess products and services

NATCO Pharma updates on legal proceedings on Risdiplam launch in India

NATCO has decided to price the product at Rs.15, 900 MRP consistent with the company’s stand before the court

Bionova opens Fremont process development and pilot plant

Toray develops membrane doubling filtration for biopharmaceutical manufacturing processes

The company will initially supply prototypes to diverse customers to evaluate in purification processes for producing gene therapy drugs with a view to swift commercialization

Sartorius Stedim Biotech opens center for bioprocess innovation in USA

New research labs and process development services to enable next generation therapeutics

BlueRock Therapeutics’ investigational cell therapy bemdaneprocel for Parkinson’s disease shows positive data at 24-months

At 24 months, data from the Phase 1 exPDite trial continue to show a favorable safety profile in all 12 participants in the trial’s high and low dose cohorts

Apollo Hospitals Chennai reaches 6,000+ successful robotic procedure

The robotic surgery program has continually pushed the boundaries of medical technology

Merck Life Science inks MoU with ICAR-CIFT, Kochi for research in fishing process

BlueRock Therapeutics receives FDA RMAT designation for Parkinson’s disease cell therapy candidate bemdaneprocel

Bemdaneprocel is the most clinically advanced investigational cell therapy in the U.S. for treating patients living with Parkinson’s disease